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Abstract
Introduction—While chronic degenerative arthropathy is the main morbidity of hemophilia, a 
very high prevalance of low bone density is also seen in men and boys with hemophilia. The 
current study investigates bone degradation in the knee joint of hemophilic mice resulting from 
hemarthrosis and the efficacy of aggressive treatment with factor VIII in the period surrounding 
injury to prevent bone pathology.
Methods—Skeletally mature factor VIII knock-out mice were subjected to knee joint 
hemorrhage induced by puncture of the left knee joint capsule. Mice received either intravenous 
Factor VIII treatment or placebo immediately prior to injury and at hours 4, 24, 48, 72 and 96 after 
hemorrhage. Mice were euthanized two-weeks after injury and the joint morphology and loss of 
bone in the proximal tibia was assessed using microCT imaging.
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Results—Quantitative microCT imaging of the knee joint found acute bone loss at the proximal 
tibia following injury including loss of trabecular bone volumetric density and bone mineral 
density, as well as trabecular connectivity density, number, and thickness. Unexpectedly, joint 
injury also resulted in calcification of the joint soft tissues including the tendons, ligaments, 
menisci, and cartilage. Treatment with factor VIII prevented this bone and soft tissue 
degeneration.
Conclusion—Knee joint hemorrhage resulted in acute changes of adjacent bone including loss 
of bone density and mineralization of joint soft tissues. The rapid calcification and loss of bone 
has implications for the initiation and progression of osteoarthritic degradation following joint 
bleeding.
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Introduction
The most common complication of severe hemophilia is recurrent hemarthrosis, which may 
lead to destruction of joints. In addition to joint damage, low bone density has been observed 
in adults [1–4] and children [5] with hemophilia. In children, early institution of regular 
prophylactic clotting factor infusions to prevent hemarthrosis helps preserve joint function 
and is the standard of care in resource-rich countries [6]. While indirect evidence suggests 
that primary prophylaxis preserves bone mineral density [7, 8], there is little information 
available on acute and subacute bone response to joint bleeding.
The potential significance is great because acute changes in the bone can impact whole joint 
function. There is evidence that chronic exposure of the joints to blood in hemophilia leads 
to destruction of both cartilage [9, 10] and bone [11] resulting in osteoarthritis as well as 
consequent deficits in postural balance [12] and gait abnormalities [13]. In addition, 
alterations to the joint tissues may lead to joint instability [14–16], which is one of the 
primary factors for the onset and progression of osteoarthritis in patients with ligament 
injuries [17]. This initial damage could contribute to recurrent joint bleeding, further 
accelerating degradation of the joint. In addition, low bone density in the subchondral bone 
has been related to osteoarthritic joint degradation [18]
This study uses microCT imaging to investigate the acute bone loss in the periarticular bone 
following induced joint bleeding in factor VIII gene knockout (FVIII−/−) mice and the 
efficacy of aggressive treatment with recombinant factor VIII(FVIII) following joint injury.
Materials and Methods
All investigations were approved by the University of North Carolina-Chapel Hill 
Institutional Animal Care and Use Committee. FVIII−/−mice generated by gene targeting 
(E16 FVIII B6;129S4-F8tm1kaz) were originally supplied by Dr. H. H. Kazazian Jr. 
(University of Pennsylvania, PA, USA) [19, 20] and bred in house. Twenty-two week old 
(skeletally mature) FVIII−/− male mice were subjected to knee joint hemorrhage induced by 
Lau et al. Page 2













puncture of the knee joint capsule with a 30.5 gauge needle, followed by instillation of 5 
microliters of saline into the left knee joint space [21] ; the contralateral right knee joint 
served as the uninjured control. One group of injured mice received intravenous (I.V.) FVIII 
treatment (n=9), and the placebo group of injured mice was injected with I.V. saline (n=9). 
Thirty minutes prior to the joint hemorrhage mice received an I.V. dose of human 
recombinant FVIII 250 IU kg−1 (AdvateTM; Baxter Bioscience, Deerfield, IL) by tail vein 
injection. At hours 4, 24, 48, 72 and 96 after the induction of bleeding, 250 IU kg−1 doses of 
FVIII were repeated. The FVIII dose was selected based on our preliminary studies and 
those of other investigators [22] demonstrating that plasma from FVIII−/− mice that receive 
this dose has the same clotting time in seconds as does plasma from hemostatically normal 
wild type mice, as measured by the activated partial thromboplastin time assay.
Two weeks after hemarthrosis, the mice were euthanized and the hind limbs were collected 
and fixed in formalin. Hind limbs were scanned at 10µm resolution using microCT (µct80; 
Scanco Medical AG, Brüttisellen, Switzerland). MicroCT analysis was performed on the 
trabecular bone at the proximal tibia, inferior to the growth plate, which is a common 
skeletal site for analysis. Histomorphometric analysis was performed on the trabecular bone 
using the Scanco analysis software to calculate parameters including trabecular bone 
volumetric density (BV/TV), trabecular connectivity density, trabecular number and 
thickness, bone tissue mineral density, and volumetric bone mineral density (vBMD). The 
BV/TV metric indicates how much trabecular bone is present for a given volume or size of 
bone. The trabecular connectivity density, number, and thickness are all structural 
microarchitectural parameters that can correlate with bone strength. The bone mineral 
density is the average density of the bone present, while the vBMD measures the average 
mineral density over the entire trabecular compartment, including the space between the 
bone tissue, which is similar to that of a clinical DEXA bone density scan.
Upon observing gross calcifications on the microCT scans, a more detailed observation of 
each specimen was performed using three-dimensional renderings using OsiriX Medical 
Imaging Viewer (www.osirix-viewer.com) to look for abnormal morphologies and 
calcifications resulting from injury. In addition, Mimics Innovation Suite (Materialise, 
Leuven Belgium) was used to segment calcified regions from the bone based on 
thresholding and image processing of the microCT data.
So as to be certain that the injury did result in exposure of the joint to blood, separate groups 
of FVIII−/− mice (n = 6 mice), not included in the evaluation of bone health, received either 
I.V. recombinant FVIII 250 IU kg−1 or I.V. saline thirty minutes prior to undergoing an 
induced hemarthrosis so as to reproduce identical conditions to those used in the bone health 
study. All of the mice were sacrificed at 4 hours after the injury and the injured legs were 
dissected free. Half of the injured joints were opened for direct visual examination for gross 
blood in the intra-articular space. The direct visual examination destroys the architecture of 
the intact joint, so the other half of the joints were left intact and processed for microscopic 
examination for blood by histology at 4 hours after the injury.
The statistical significance of the drug treatment and injury were determined using a two-
way ANOVA with Tukey Test. (SigmaPlot). Significance was also determined using a two-
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sided t-test to assess changes resulting from joint injury between the placebo and drug 
treated mice using the contra-lateral uninjured limb as an internal control.
Results
The study quantifies the changes of the bone at the proximal tibia that result following 
hemarthrosis in the adjacent joint in FVIII−/−mice. This joint injury resulted in an acute 
reduction of proximal tibial BV/TV, trabecular connectivity density and thickness, bone 
tissue mineral density, and volumetric bone mineral density (vBMD) (Fig.1 and Fig. 2C, 
inset). This damage was mitigated by aggressive FVIII replacement (Fig. 1 and Fig 2D, 
inset)..
In the absence of FVIII replacement joint injury was associated with a 25% decrease in bone 
volumetric density (BV/TV) (p<0.05), 13% decrease in trabecular thickness (p<0.05), 5% 
decrease in tissue mineral density (p<0.05), and 27% decrease in vBMD (p<0.05) compared 
to the contralateral uninjured limb (Fig. 1). Mice that received the extended FVIII treatment 
showed no significant changes in any of these bone metrics (Fig. 1).
The difference between the injured and the uninjured contralateral limb of the individual 
mice in each treatment group (placebo or FVIII-treated) was calculated. The mean % change 
of the individual animals was derived for each treatment approach. Compared to the changes 
in the placebo-treated FVIII−/− mice, FVIII replacement significantly prevented bone 
degradation when measured by BV/TV (p<0.05), trabecular thickness, (p<0.05),tissue 
mineral density (p<0.05), and vBMD (p<0.05).Also, there was a strong trend for reduction 
in trabecular connectivity density(p=0.055) and trabecular number (p=0.055) (Table 1).
Direct visual examination of joints collected at four hours after this induced joint 
hemorrhage demonstrated gross bleeding within the joint capsule and in the adjacent soft 
tissue of the injured untreated mice and in the mice that had received a single FVIII infusion 
prior to wounding. Additional joints from this time point that were left intact and processed 
for histologic staining also showed that blood was present at four hours after the joint 
capsule puncture in the mice from both groups. Scattered areas of red blood cells layering 
along the synovial lining of the joint were present in the FVIII-treated mice, whereas in the 
placebo-treated mice a larger volume of blood partially filled the intra-articular space
In the unprotected (normal saline placebo treated) group, joint injury resulted in acute 
morphological changes to the cortical bone in the surrounding joint, with the periosteal wall 
becoming rough (Fig.2C). These damaged regions were observed on the articular surface of 
the distal femur and proximal tibia, as well as the patella and fibula (Fig.2C and Fig.3 Left). 
In addition, the patella of the injured and degraded joint was displaced, consistent with 
hemorrhage and edema. Joints that were injured in mice treated with FVIII did not show 
these morphological changes (Fig. 2D and Fig.3 Center).
Gross mineralization was found on the femur, tibia, and fibula tendon insertion points, as 
well as the patella, patellar tendon, menisci, ligaments and cartilage (Fig.3 Left) of injured 
joints from the placebo group of mice. A more detailed analysis of the calcifications in the 
distal femur using the Mimics image processing software found that the calcified segment 
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had a lower mineral density (1086 mgHA/cm3) compared to the adjacent cortical bone 
(1449mgHA/cm3) (Fig. 4), so that a volume of the calcified region of 0.014 mm3 could be 
delineated. Mineral density is given in units of milligrams of Hydroxyapatite per 
cm3(mgHA/cm3).The FVIII treatment prevented this acute mineralization as these 
calcifications were not observed in injured limbs of FVIII treated mice nor non-injured 
limbs (Fig. 2A, 2B, and Fig.3 Center and Right, Fig. 4).
Discussion and Conclusion
The high prevalence of low bone mineral density in men and boys with hemophilia is likely 
multifactorial. Low bone density has been attributed to the chronic effect of decreased 
physical activity and disuse atrophy following the development of hemarthropathy, as well 
as to the chronic effects of HIV and hepatitis infection and their therapies [2]. This study 
shows that induced joint hemorrhage in hemophilic mice results in an acute loss of 
trabecular bone in the injured joint as early as 2 weeks after injury. Aggressive replacement 
of FVIII prevented the deterioration of these morphologic parameters of bone as well as the 
rapid mineralization in the joint tissues following joint bleeding. Our findings support the 
hypothesis that reduced bone density in the setting of hemophilia may, at least in part, be 
secondary to acute hemorrhage and the cumulative effect of acute bleeds.
While measures were taken to have similar weights for both groups of mice, the drug treated 
group had a slightly larger average weight (26.5 ± 1.9 vs 25.0 ± 2.4 grams), even though this 
difference is not statistically significant (p=0.16). Any contribution from weight difference 
was normalized by directly comparing the % change between the injured and non-injured 
limb within each animal (Table 1).
Intriguingly, one group of investigators has recently reported that in the absence of observed 
hemorrhage, hemophilia A mice have statistically significant diminution of bone density 
when compared to their hemostatically normal littermates [23, 24]. These authors concluded 
that low bone density is an inherent phenotype that is independently associated with 
congenital coagulation FVIII deficiency and is the subject of further mechanistic 
investigation [25]. All mice in both our study cohorts were FVIII deficient throughout 
skeletal maturation and the observed impact of joint hemorrhage, occurring after skeletal 
maturation, upon bone degeneration is independent of any phenotypic osteopenia that might 
be a characteristic of congenital FVIII deficiency, per se. Hemarthrosis caused a 25% 
decrease in trabecular bone BV/TV with some individual mice losing over 30%. This rapid 
loss of bone density has implications as relates to the onset of osteoarthritis [26]. Changes in 
the subchondral bone could affect the cartilage and other soft tissues of the joint contributing 
to osteoarthritis [14, 27].
Uncontrolled bleeding in this experimental model of hemarthrosis is not only associated 
with acute intra-articular inflammation [28–30] and loss of bone density in the adjacent 
tibia, but is additionally associated in our study with rapid calcification of the joint soft 
tissues. Acute mineralization of the joint following joint bleeding and associated 
inflammation could have long term consequences. Calcification in the joint poses a risk for 
arthritic joint degeneration and has been associated clinically with osteoarthritis in both the 
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hip and the knee [31–33]. In addition, tendon calcification has been correlated with 
structural joint disease [34]. Calcification alters the material behavior of these tissues, 
leading to altered joint biomechanics, which could further degrade the joint and joint tissues. 
Tendon calcification has been found to lead to degradation of the tissue [35]. In the knee 
joint, calcifications following injury have been observed clinically at 6-months post-injury 
[36], which has implications for long term degeneration. Future work could use this mouse 
joint hemorrhage model to investigate the progression of joint degradation and the onset of 
osteoarthritis associated with these gross soft tissue calcifications following joint injury and 
inflammation.
The mechanisms by which exposure of the joint to blood causes these acute morphologic 
changes warrant further investigation. Increased expression of receptor activator of nuclear 
factor-κB (RANK) and RANK ligand and decreased expression of osteoprotegerin have 
been demonstrated in synovial tissue of hemophilic joints, suggesting increased unopposed 
osteoclastic activity, however these studies were performed on joints with end-stage 
pathology, resulting from very chronic bleeding [37]. Instead, the current study uses a small 
needle injury in hemophilic mice to initiate joint bleeding and inflammation and examines 
acute pathologic changes. It is unknown whether the inflammatory response that occurs 
following exposure of the joint to blood involves identical mechanisms in hemophilic 
individuals and in non-hemophilic individuals who experience hemarthrosis. All animals in 
the current study were congenitally FVIII deficient and our ongoing work compares the 
response to intra-articular blood in hemostatically normal and hemophilic animals. Future 
work is needed to investigate the similarities in the pathology of rapid calcifications 
observed in this study compared to those that have been described in individuals without 
hemophilia receiving traumatic injury to the joint that results in hematoma and inflammation 
[36] .
In conclusion, these data support the role of acute hemarthrosis in the absence of FVIII in 
hemophilia-related bone loss. Whether joint injury is the primary cause of bone loss or a 
contributing factor deserves further study. Hemophilic joint bleeding tends to recur, 
establishing a vicious cycle of hemorrhage in affected “target” joints [38]. Our ongoing 
studies examine the extent and time course of resolution of bone loss following a single or 
repetitive hemarthroses, and whether full resolution does occur between bleeding episodes. 
For the studies reported here we chose an aggressive treatment with FVIII replacement 
throughout wound healing. This treatment schedule essentially reversed the bleeding 
phenotype of FVIII−/− mice. Our ongoing studies examine whether more abbreviated 
approaches to FVIII replacement (as are typically used in the clinical treatment of 
hemophilic bleeding) can achieve bone preservation in this model. Additionally, the rapid 
mineralization of the joint soft tissues warrants further study to investigate how these 
calcifications affect arthritic joint health and the progression to osteoarthritis. Overall, this 
study contributes to an understanding of the underlying cause of low bone density in the 
setting of FVIII deficiency and identifies calcification in the joint that could be an initiator 
of osteoarthritic degenerative joint disease.
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Properties of bone measured by microCT in the proximal tibia adjacent to the joint at two 
weeks following unilateral induced joint hemorrhage. Separate groups of FVIII−/− mice 
were treated with either Placebo (physiologic saline) or with recombinant FVIII. Trabecular 
bone volumetric density (BV/TV), Trabecular Thickness, Trabecular Connectivity Density, 
and Trabecular Number, Volumetric bone mineral density (vBMD) and Bone Tissue 
Mineral Density (mean±SEM) for injured/uninjured limbs of placebo-treated compared to 
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FVIII-treated mice (* denotes statistical significance p<0.05 for the difference between 
injured and uninjured within each treatment group).
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Three-dimensional rendering of the joint from microCT imaging for the uninjured (A & B) 
and injured (C & D) knee from the placebo (A & C) and FVIII treated (B & D) mice. The 
blue inset for each condition is an image of the trabecular bone region of analysis of the 
proximal tibia, demonstrating less bone in the injured, placebo-treated mouse.
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Left: Injured knee joint from placebo-treated FVIII−/− mouse showing calcification of the 
patella, patellar tendon, menisci, ligaments, and cartilage. Calcifications rendered in green. 
Center: Injured knee from FVIII-treated mouse does not have this mineralization present. 
Right: Uninjured knee from placebo-treated mouse does not have mineralization present
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Top: Axial, cross-sectional image of the distal femur from injured (left) and uninjured 
(right) limb from a placebo-treated mice. Calcifications of the patellar tendon and distal 
femur tendon insertion rendered in green. Profile analysis line spans from the endosteal 
surface (circle) to the edge of the calcification (arrow). Bottom: Corresponding intensity 
values along the red (injured limb)and blue (uninjured limb) profile lines shown in above 
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images (location of the circle is at x=0 on the graph). Areas of calcification had lower 
density (1086 mgHA/cc) than the cortical bone (1449mgHA/cc).
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